| Literature DB >> 29192554 |
Oscar R Sierra Matiz1,2,3,4,5, Juliana Santilli1,2,3,4,5, Leticia A Anai1,2,3,4,5, Maria C L Da Silva1,2,3,4,5, Felipe A Sueiro1,2,3,4,5, Júlio L Sequeira1,2,3,4,5, Larissa F Magalhães1,2,3,4,5, Geórgia M Magalhães1,2,3,4,5, Mirela Tinucci Costa1,2,3,4,5, Sabryna G Calazans1,2,3,4,5.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in dogs. We evaluated Ki67 immunoexpression and mitotic index (MI) in dogs diagnosed with DLBCL and treated with a 19-wk CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) protocol. Twenty-nine lymph node samples from dogs diagnosed with DLBCL were analyzed for Ki67 immunostaining, and positive cells present in 1 cm2 were counted in a grid reticle for comparison of survival times above and below the means. The Ki67 mean was 107, and the MI mean was 21. There was a significant ( p < 0.05) difference in median survival time between Ki67 immunostaining above and below the mean, with no difference in MI groups. Ki67 values >107 positive cells per 5 HPF counted in a grid reticle were associated with shorter survival times in dogs with DLBCL treated with a 19-wk CHOP-based protocol.Entities:
Keywords: Cell proliferation; dogs; immunohistochemistry; mitosis; prognosis
Mesh：
Substances：
Year: 2017 PMID： 29192554 PMCID： PMC6505881 DOI： 10.1177/1040638717743280
Source DB: PubMed Journal: J Vet Diagn Invest ISSN： 1040-6387 Impact factor: 1.279